fasudil has been researched along with Glaucoma in 4 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Glaucoma: An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fasudil hydrochloride (Fas), a rho-associated protein kinase inhibitor, proved to be promising for glaucoma management owing to its IOP lowering and antioxidant effects." | 8.12 | Exploring a Novel Fasudil-Phospholipid Complex Formulated as Liposomal Thermosensitive in situ Gel for Glaucoma. ( Ahmed, MF; El-Moslemany, RM; Khalafallah, NM; Khallaf, AM; Morsi, MH, 2022) |
| "Fasudil hydrochloride (Fas), a rho-associated protein kinase inhibitor, proved to be promising for glaucoma management owing to its IOP lowering and antioxidant effects." | 4.12 | Exploring a Novel Fasudil-Phospholipid Complex Formulated as Liposomal Thermosensitive in situ Gel for Glaucoma. ( Ahmed, MF; El-Moslemany, RM; Khalafallah, NM; Khallaf, AM; Morsi, MH, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Donegan, RK | 1 |
| Lieberman, RL | 1 |
| Abbhi, V | 1 |
| Saini, L | 1 |
| Mishra, S | 1 |
| Sethi, G | 1 |
| Kumar, AP | 1 |
| Piplani, P | 1 |
| Khallaf, AM | 1 |
| El-Moslemany, RM | 1 |
| Ahmed, MF | 1 |
| Morsi, MH | 1 |
| Khalafallah, NM | 1 |
| Seto, M | 1 |
| Asano, T | 1 |
2 reviews available for fasudil and Glaucoma
| Article | Year |
|---|---|
Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.
Topics: Adrenergic Agonists; Adrenergic Antagonists; Adrenergic beta-Antagonists; Animals; Drug Discovery; G | 2016 |
[Rho-kinase inhibitors].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Clinical Trials as Topic; Coronary A | 2011 |
2 other studies available for fasudil and Glaucoma
| Article | Year |
|---|---|
Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Disease Models, Animal; Dose-Response Relationship | 2017 |
Exploring a Novel Fasudil-Phospholipid Complex Formulated as Liposomal Thermosensitive in situ Gel for Glaucoma.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Gels; Glaucoma; Liposomes; Particle Size; Ph | 2022 |